GLP1R and diabetes mellitus: Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established therapies for diabetes and obesity, heart transplant recipients have been excluded from pivotal trials due to concerns regarding gastrointestinal intolerance, altered drug absorption, and possible interactions with immunosuppressants.